S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

from OncLive® On Air · host OncLive® On Air

Drs Hanna and Kandula discuss the significance of the FDA approval of toripalimab in nasopharyngeal carcinoma; pivotal data from the JUPITER-02 and POLARIS-02 trials; and how the addition of toripalimab to the nasopharyngeal carcinoma treatment armamentarium increases the importance of multidisciplinary collaboration.

Episode metadata supplied by the publisher feed · Published Dec 4, 2023

Embed this episode

Attribution link and audio player

NOW PLAYING

S9 Ep46: FDA Approval Insights: Toripalimab in Recurrent/Metastatic Nasopharyngeal Carcinoma

0:00 17:17

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of OncLive® On Air?

This episode is 17 minutes long.

When was this OncLive® On Air episode published?

This episode was published on December 4, 2023.

Can I download this OncLive® On Air episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!